Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
July 02, 2018 16:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, July 02, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces Pricing of $67 Million Public Offering of Common Stock
June 28, 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, June 28, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces Commencement of Public Offering of Common Stock
June 27, 2018 16:01 ET
|
Kura Oncology, Inc.
SAN DIEGO, June 27, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Appoints Chief Operating Officer, Expands Clinical Development Team as Company Prepares for First Registration-Directed Trial
June 20, 2018 07:30 ET
|
Kura Oncology, Inc.
– John Farnam appointed to newly created position of Chief Operating Officer – – Bridget Martell, M.D., and Blake Tomkinson, Ph.D., join as Vice Presidents of Clinical Development – –...
Kura Oncology to Present at JMP Securities Life Sciences Conference
June 14, 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, June 14, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
OncoDNA announces screening collaboration with Kura Oncology
May 22, 2018 07:00 ET
|
Kura Oncology, Inc.
- OncoDNA to support patient enrolment for Kura Oncology’s Phase II trial of tipifarnib- Agreement demonstrates OncoDNA’s biopharma partnership strategy GOSSELIES, Belgium, May 22, 2018 (GLOBE...
Kura Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 08, 2018 16:05 ET
|
Kura Oncology, Inc.
– Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) on track to initiate in second half of 2018 – – Data from multiple Phase 2 trials of...
Kura Oncology to Present at Deutsche Bank 43rd Annual Health Care Conference
May 03, 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 03, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces New Patent for Tipifarnib in Hematologic Malignancies
May 02, 2018 07:30 ET
|
Kura Oncology, Inc.
– Newly issued patent expands protection for tipifarnib in U.S., provides exclusivity in certain CXCL12-expressing cancers to 2037 – – Second U.S. patent for tipifarnib reinforces potential for...
Kura Oncology to Report First Quarter 2018 Financial Results
May 01, 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 01, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...